2 results
Approved WMORecruiting
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…
Approved WMOPending
We aim to assess whether risk modification effectiveness is visible on follow-up CT and in biomarker values when comparing baseline with 12 months follow-up in patients without significant obstructive coronary artery disease on coronary Ct. We also…